Cetera Investment Advisers
VRTX icon

Cetera Investment Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History

Cetera Investment Advisers’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.4M Sell
72,633
-2,380
-3% -$1.11M 0.03% 503
2025
Q4 		$34M Sell
75,013
-2,701
-3% -$1.16M 0.04% 453
2025
Q3 		$30.4M Buy
77,714
+17,518
+29% +$7.32M 0.04% 484
2025
Q2 		$26.8M Sell
60,196
-4,578
-7% -$2.11M 0.05% 416
2025
Q1 		$31.4M Buy
64,774
+10,817
+20% +$5.04M 0.06% 328
2024
Q4 		$21.7M Buy
53,957
+328
+0.6% +$152K 0.05% 400
2024
Q3 		$24.9M Buy
53,629
+1,616
+3% +$776K 0.05% 358
2024
Q2 		$24.4M Buy
52,013
+1,146
+2% +$497K 0.06% 344
2024
Q1 		$21.3M Buy
50,867
+33,530
+193% +$14.2M 0.05% 369
2023
Q4 		$7.05M Buy
17,337
+1,531
+10% +$566K 0.06% 329
2023
Q3 		$5.5M Buy
15,806
+425
+3% +$149K 0.05% 384
2023
Q2 		$5.41M Buy
15,381
+1,464
+11% +$493K 0.05% 383
2023
Q1 		$4.38M Sell
13,917
-1,060
-7% -$318K 0.04% 431
2022
Q4 		$4.33M Buy
14,977
+5,200
+53% +$1.58M 0.04% 429
2022
Q3 		$2.83M Sell
9,777
-941
-9% -$271K 0.06% 352
2022
Q2 		$3.02M Sell
10,718
-3,396
-24% -$909K 0.05% 389
2022
Q1 		$3.68M Buy
14,114
+544
+4% +$129K 0.05% 359
2021
Q4 		$2.98M Sell
13,570
-312
-2% -$60.7K 0.04% 427
2021
Q3 		$2.52M Sell
13,882
-819
-6% -$160K 0.04% 441
2021
Q2 		$2.96M Buy
14,701
+868
+6% +$182K 0.05% 403
2021
Q1 		$2.97M Sell
13,833
-3,368
-20% -$740K 0.06% 328
2020
Q4 		$4.07M Buy
17,201
+12,157
+241% +$2.79M 0.08% 268
2020
Q3 		$1.37M Buy
5,044
+3,738
+286% +$1.03M 0.11% 206
2020
Q2 		$379K Buy
+1,306
New +$354K 0.04% 414
2018
Q4 		– Sell
-1,128
Closed -$217K – 508
2018
Q3 		$217K Buy
+1,128
New +$201K 0.03% 445

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Cetera Investment Advisers's VRTX Position: Q1 2026 in Review

Cetera Investment Advisers reduced its Vertex Pharmaceuticals (VRTX) stake by 3.2% in Q1 2026, selling an estimated $1.11M and leaving 72,633 shares worth $32.4M. The position accounts for 0.03% of the portfolio, ranked #503.

Cetera Investment Advisers first reported a position in VRTX in Q3 2018 and has held it in 25 quarters since. The position peaked at $34M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Cetera Investment Advisers held 72,633 shares of Vertex Pharmaceuticals worth $32.4M as of Q1 2026.
  • Cetera Investment Advisers sold 2,380 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.11M.
  • Vertex Pharmaceuticals made up 0.03% of Cetera Investment Advisers's portfolio in Q1 2026, its #503 holding.
  • Cetera Investment Advisers first reported a position in Vertex Pharmaceuticals in Q3 2018 and has held it in 25 quarters since.
  • Cetera Investment Advisers's Vertex Pharmaceuticals position peaked at $34M in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.